Cancer vaccine developer Agenus has inked a licensing, development and manufacturing technology transfer agreement with Russian drug company NewVac. Under the deal, NewVac gets to manufacture, market...
Now that Provenge and Yervoy have been approved, specialists are keying in on a new generation of immunotherapies that promise to change the standard of care for cancer. As Stephen Hodi, director of
GlaxoSmithKline isn't the only company cheering the launch of a late-stage program for a shingles vaccine that could prove to be a blockbuster. Antigenics flagged its own role in the parade and was
GlaxoSmithKline isn't the only company cheering this week's launch of a late-stage program for a shingles vaccine. Antigenics flagged its own role in the parade for the potential blockbuster and was
Shares of Antigenics (AGEN) got some much-needed help after the developer reported that its vaccine/adjuvant combo to guard against genital herpes looked promising in a small, early-stage trial. The
A new brain tumor vaccine designed to use a patient's own cells is now in mid-stage trials and could offer new hope to patients who have already undergone therapy. The Cleveland Plain Deal profiles
As China has been to drug manufacturing (think heparin), so Russia is becoming to drug development. Management needs to scrutinize the data-collection processes of clinical trials conducted there.
Antigenics has spent hundreds of millions of dollars on the late-stage development of the cancer vaccine Oncophage, but its CEO tells Mass High Tech that the FDA's mindset on cancer drug development
Antigenics (AGEN) has a fresh round of sour news to report this morning, announcing that European regulators will soon formally reject its kidney cancer vaccine Oncophage. The biotech said that it
Shares of Antigenics surged for three straight days this week after researchers released new data backing its kidney cancer vaccine Oncophage. Investors pushed the stock straight up after hearing